These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 8879874)
1. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Deshmukh A; Scott JA; Palmer EL; Hochberg FH; Gruber M; Fischman AJ Clin Nucl Med; 1996 Sep; 21(9):720-5. PubMed ID: 8879874 [TBL] [Abstract][Full Text] [Related]
2. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205 [TBL] [Abstract][Full Text] [Related]
3. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. Buchpiguel CA; Alavi JB; Alavi A; Kenyon LC J Nucl Med; 1995 Jan; 36(1):159-64. PubMed ID: 7799071 [TBL] [Abstract][Full Text] [Related]
4. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028 [TBL] [Abstract][Full Text] [Related]
5. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Patronas NJ; Di Chiro G; Brooks RA; DeLaPaz RL; Kornblith PL; Smith BH; Rizzoli HV; Kessler RM; Manning RG; Channing M; Wolf AP; O'Connor CM Radiology; 1982 Sep; 144(4):885-9. PubMed ID: 6981123 [TBL] [Abstract][Full Text] [Related]
6. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862 [TBL] [Abstract][Full Text] [Related]
11. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Kim EE; Chung SK; Haynie TP; Kim CG; Cho BJ; Podoloff DA; Tilbury RS; Yang DJ; Yung WK; Moser RP Radiographics; 1992 Mar; 12(2):269-79. PubMed ID: 1561416 [TBL] [Abstract][Full Text] [Related]
12. Tl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis. Siepmann DB; Siegel A; Lewis PJ Clin Nucl Med; 2005 Mar; 30(3):199-200. PubMed ID: 15722830 [No Abstract] [Full Text] [Related]
13. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera--a pilot study. Stokkel M; Stevens H; Taphoorn M; Van Rijk P Nucl Med Commun; 1999 May; 20(5):411-7. PubMed ID: 10404525 [TBL] [Abstract][Full Text] [Related]
14. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. Valk PE; Budinger TF; Levin VA; Silver P; Gutin PH; Doyle WK J Neurosurg; 1988 Dec; 69(6):830-8. PubMed ID: 2848111 [TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Sonoda Y; Kumabe T; Takahashi T; Shirane R; Yoshimoto T Neurol Med Chir (Tokyo); 1998 Jun; 38(6):342-7; discussion 347-8. PubMed ID: 9689817 [TBL] [Abstract][Full Text] [Related]